EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity

Tikhon V Savin iD, Vladimir V Kopat iD, Elena D Danilenko, Alexey A Churin iD, Anzhelika M Milichkina, Edward S Ramsay iD, Ilya V Dukhovlinov, Andrey S Simbirtsev, Areg A Totolian iD

Viruses · 2025

DOI: 10.3390/v17091186 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Tikhon V Savin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Saint Petersburg Pasteur Institute, Mira St. 14, 197101 St. Petersburg, Russia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Skin Tests, T-Lymphocytes. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel skin test for an in vivo assessment of SARS-CoV-2-specific T-cell immunity was developed using CoronaDermPS, a multiepitope recombinant polypeptide encompassing MHC II–binding CD4+ T-cell epitopes of the SARS-CoV-2 structural proteins (S, E, M) and full length nucleocapsid (N). In silico epitope prediction and modeling guided antigen design, which was expressed in Escherichia coli, was purified (>95% purity) and formulated for intradermal administration. Preclinical evaluation in guinea pigs, mice, and rhesus macaques demonstrated a robust delayed type hypersensitivity (DTH) response at optimal doses (10–75 µg), with no acute or chronic toxicity, mutagenicity, or adverse effects on reproductive organs. An integrated clinical analysis included 374 volunteers stratified by vaccination status (EpiVacCorona, Gam-COVID-Vac, CoviVac) prior to COVID-19 infection (Wuhan/Alpha, Delta, Omicron variants), and SARS-CoV-2–naïve controls. Safety assessments across phase I–II trials recorded 477 adverse events, of which >88% were mild and self-limiting; no severe or anaphylactic reactions occurred. DTH responses were measured at 24 h, 72 h, and 144 h post-injection by papule and hyperemia measurements. Overall, 282/374 participants (75.4%) exhibited a positive skin test. Receiver operating characteristic analysis yielded an overall AUC of 0.825 (95% CI: 0.726–0.924), sensitivity 79.5% (95% CI: 75.1–83.3%), and specificity 85.5% (95% CI: 81.8–88.7%), with comparable diagnostic accuracy across vaccine, and variant subgroups (AUC range 0.782–0.870). CoronaDerm-PS–based skin testing offers a simple, reproducible, and low-cost method for qualitative evaluation of T-cell–mediated immunity to SARS-CoV-2, independent of specialized laboratory equipment (Eurasian Patent No. 047119). Its high safety profile and consistent performance across diverse cohorts support its utility for mass screening and monitoring of cellular immune protection following infection or vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Skin TestsT-LymphocytesHumansAnimalsEpitopes, T-LymphocyteMacaca mulattaMaleFemaleMiddle AgedAdultMiceCOVID-19 VaccinesHypersensitivity, DelayedYoung AdultImmunity, CellularAged

Stichwörter der Autor:innen

CorD_PSCoronaDerm-PSDTHSARS-CoV-2cell-mediated immunityskin test

Substanzen

Epitopes, T-LymphocyteCOVID-19 Vaccines

Autor:innen und Institutionen

  • Saint Petersburg Pasteur Institute, Mira St. 14, 197101 St. Petersburg, Russia.
  • Department of Immunology, Pavlov First State Medical University of St. Petersburg, L'va Tolstogo St. 6-8, 197022 St. Petersburg, Russia.
  • LLC "ATG Service Gene", Maly Prospekt of Vasilievsky Island 57, Building 4, 199178 St. Petersburg, Russia.
  • Institute of Medical Biotechnology, State Research Centre of Virology and Biotechnology "Vector", Khimzavodskaya St. 9, 633009 Berdsk, Novosibirsk Region, Russia.
  • Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Lenin Avenue 3, 634028 Tomsk, Russia.

ORCID-Profile: Tikhon V Savin, Vladimir V Kopat, Alexey A Churin, Edward S Ramsay, Areg A Totolian

Zitieren

APA

Savin, T. V., Kopat, V. V., Danilenko, E. D., Churin, A. A., Milichkina, A. M., Ramsay, E. S., Dukhovlinov, I. V., Simbirtsev, A. S., & Totolian, A. A. (2025). Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity. Viruses. https://doi.org/10.3390/v17091186

Vancouver

Savin TV, Kopat VV, Danilenko ED, Churin AA, Milichkina AM, Ramsay ES, et al. Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity. Viruses. 2025. doi:10.3390/v17091186

BibTeX
@article{Savin2025,
  author = {Savin, Tikhon V and Kopat, Vladimir V and Danilenko, Elena D and Churin, Alexey A and Milichkina, Anzhelika M and Ramsay, Edward S and Dukhovlinov, Ilya V and Simbirtsev, Andrey S and Totolian, Areg A},
  title = {Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17091186}
}
Kostenlos starten →